title: Open letter to the Executive Director of the European Medicines Agency concerning the licensing of hydroxyethyl starch solutions for fluid resuscitation.
authors.forename: R
authors.initials: R
authors.lastname: Bellomo
authors.forename: J
authors.initials: J
authors.lastname: Bion
authors.forename: S
authors.initials: S
authors.lastname: Finfer
authors.forename: J
authors.initials: J
authors.lastname: Myburgh
authors.forename: A
authors.initials: A
authors.lastname: Perner
authors.forename: K
authors.initials: K
authors.lastname: Reinhart
mesh_terms: D005060:Europe; D005440:Fluid Therapy / Q000592:standards*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects / Q000592:standards*; D008004:Licensure; D019999:Pharmaceutical Solutions / Q000592:standards; D060735:Pharmacovigilance; D010952:Plasma Substitutes / Q000009:adverse effects / Q000592:standards*; D057051:Product Recalls and Withdrawals; D012151:Resuscitation / Q000592:standards*
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D019999:Pharmaceutical Solutions; D010952:Plasma Substitutes